Sun Pharma’s stock goes up following the release of earnings report

Sun Pharmaceutical Industries saw an increase in its share price following a significant rise in consolidated net profit for the third quarter ending December 31, 2025. The stock closed nearly 1% higher at Rs 1,610.20 on the BSE, reaching a high of 3.81% during the day at Rs 1,655.80.

Similarly, on the NSE, the stock rose by 0.92% to finish at Rs 1,610.10, with an intra-day high of 3.78% at Rs 1,655.70. Sun Pharmaceutical Industries reported a consolidated net profit of Rs 3,369 crore, representing a 16% increase from the previous fiscal quarter. This growth was driven by performance improvements in all business segments.

Total revenue from operations also saw an uptick, reaching Rs 15,520 crore compared to Rs 13,675 crore in the same period last year. The company’s board approved an interim dividend of Rs 11 per equity share of Re 1 for the financial year 2025-26.

Sun Pharma MD, Kirti Ganorkar, highlighted the positive results, stating, “Our results this quarter demonstrate well-rounded growth across all businesses, prominently led by our branded businesses in India, emerging markets, and global innovative medicines.” These statements emphasize the company’s success and expansion in various key markets.

The consistent growth across all business segments for Sun Pharmaceutical Industries reflects a robust performance and strategic business decisions that have contributed to their financial success. Kirti Ganorkar’s statement underscores the company’s focus on brand expansion and global market presence through innovative medicines.

With a focus on growth and diversification, Sun Pharmaceutical Industries is well-positioned to continue its successful trajectory and deliver value to shareholders. The positive financial results for the third quarter highlight the company’s stability and potential for long-term success in the pharmaceutical industry.